Identify equivocal lesions where an objective risk assessment would be helpful.
Use our device to analyse, and receive an "Investigate Further" or "Monitor" result.
Counsel your patient on next steps using the objective result to assist in your decision making.
- Simple design, effortless application
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- AI-Powered, ultra-minitiarized ESS Technology
- 97% sensitivity across common skin cancers1
- 68% decrease in missed skin cancers with use of the device2
DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.
David Leffell, M.D.
Chief, Section of Dermatologic Surgery and Cutaneous Oncology, Yale School of Medicine Scientific Advisory Board, DermaSensor
DermaSensor looks beyond the visual to improve your decision-making and confidence.
According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.2
1Manolakos D et al. Clinical Validation of a Handheld Elastic Scattering Spectroscopy Artificial Intelligence Device, Presentation at American Academy of Dermatologists Innovation Academy, July 20-24, 2022.
2Thames T et al. Clinical Utility of a Handheld Elastic Scattering Spectroscopy Tool and Machine Learning on the Diagnosis and Management of Skin Cancer. Poster Presentation, STFM Annual Spring Conference, April 30-May 4, 2022.